Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar;69(3):225-7.
doi: 10.1007/BF02734226.

Leukemia in infants

Saika Somjee  1 , Rupa Sapre, Shaila Shinde, Ashok Kumar, Subodh Dhond, Y Badrinath, Shashikant Mahadik, Anuradha Chougale, Rasheeda Ansari, C N Nair, S H Advani
Affiliations

Leukemia in infants

Saika Somjee et al. Indian J Pediatr. 2002 Mar.

Abstract

Objective: Acute Leukemia is rare in infants. It is characterized by non-specific symptomatology requiring a high index of suspicion on the part of a pediatrician for referral and diagnosis. It has peculiar biological features, unresponsiveness to treatment and poor prognosis.

Methods: Eighteen infants with acute leukemia were seen during 1994 to 2001 and were analyzed on the basis of clinical and laboratory data. There were 13 cases of Acute Lymphoblastic Leukemia (ALL), 4 cases of Acute Myeloid Leukemia (AML) and one case remained unclassifiable, as the surface markers could not be done. Morphologically 9/13 cases of ALL were of FAB L1 type and remaining of L2 subtype, and 2/4 cases of AML were of FAB M1 type and remaining of M2 subtype.

Result: Clinical data was available completely only in 11 cases. Hyperleucocytosis was present in 4 cases, organomegaly in 8 cases and lympadenopathy in 5 cases. One patient presented with a chloroma in the retrorbital region although there was no parenchymal involvement of the brain. Immunophenotyping could be done in 13 cases, where 7 cases were diagnosed as CALLA positive-ALL (HLADR+, CD19+, CD10+), 2 cases as Early Pre-B ALL (HLADR+, CD19+, CD10 negative), one as T ALL (cCD3+, CD2+, CD7+) and 3 cases as AML (CD13+, CD33+, HLADR+). None of our patients received treatment.

PubMed Disclaimer

References

    1. Blood. 2000 Jul 1;96(1):24-33 - PubMed
    1. N Engl J Med. 1998 Aug 27;339(9):605-15 - PubMed
    1. J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):152-7 - PubMed
    1. J Clin Oncol. 1999 Feb;17(2):445-55 - PubMed
    1. Blood. 1985 Nov;66(5):1115-23 - PubMed

LinkOut - more resources